Reduction in risk for range of critical outcomes greatest for daily dietary fiber intake of 25 to 29 g.
Rate of the primary outcome was similar for canagliflozin, glucagon-like peptide-1 agonist
Cardiovascular risk increased with sulfonylureas and basal insulin versus newer classes of ADM
17.1% of patients reported having experienced one or more events in previous year.
Higher risk seen on Christmas Eve, particularly in older adults with diabetes, heart disease
Updates include use of SGLT-2 inhibitors and GLP-1 receptor agonists for T2DM, CVD; endorsed by ACC
For this study, the authors identified randomized controlled trials (RCTs) that compared SGLT2 inhibitors with placebo, no treatment, or another antidiabetic agent and reported on UTI outcome.
Median of 2 strips/day used by those taking agents not considered to be risk for causing hypoglycemia
Rate has declined but remains higher in those with type 1 or 2 diabetes than in those without
Linagliptin added to usual care compared with placebo added to usual care resulted in a noninferior risk for a composite cardiovascular or renal outcome over a median 2.2 years.
Prediction independent of traditional risk factors such as MetS, glucose, HbA1c in general population
Significant additive interaction identified for night shift work, unhealthy lifestyle for female nurses
Report provides guidance on reducing CV risk in patients with T2DM and atherosclerotic CV disease
Using higher HbA1c target in over-75s could increase disability-adjusted life-years by 44.2%.
Delays in seeking care for first major symptom of macrovascular disease, first major diagnostic test.
SGLT2i reduced the risks for progression of renal disease by 45% and heart failure hospitalization by 31% in patients with type 2 diabetes.
Risk increased for lower-limb amputation, diabetic ketoacidosis compared with GLP1 receptor agonists.
Lower all-cause mortality in CABG group vs PCI-DES group after median follow-up of 7.5 years.
For patients with prediabetes, changes in risk indicators during intervention tied to T2DM, CVD risk
Treatment resulted in lower HF hospitalization rate in patients with, without atherosclerosis.
Insulin products chart with pharmacokinetic properties.
Treatment with bardoxolone methyl resulted in significant weight loss and showed no evidence of muscle wasting in patients with type 2 diabetes and stage IV chronic kidney disease.
Strict BP control, fenofibrate use may increase long-term risk for adverse kidney events in T2DM patients
In a study, reduced mortality was found among TRT users with type 2 diabetes after adjustment for cardiovascular risk factors.
The effect of Invokana on CV risk was evaluated in the CANVAS (CANagliflozin cardioVascular Assessment Study) Program in >10,000 adults with T2D who had established CV disease or were at risk for CV disease with ≥2 risk factors.
Canagliflozin vs placebo is associated with increased survival and renal outcomes in patients with type 2 diabetes and macroalbuminuria.
Fasting plasma glucose, BMI elevated 10 years before diagnosis of prediabetes, diabetes.
Study results indicated that sitagliptin showed greater glycemic efficacy than dapagliflozin treatment.
Additional focus on lifestyle management, self-management education and support emphasized
Findings based on data reweighted to reflect the adult population with diabetes in the US.
Renal and Urology News Articles
- Low Vitamin D Tied to Risk for Renal Hyperfiltration in Healthy Adults
- Novel Albuminuria Endpoints May Improve CKD Progression Trials
- Overactive Bladder Linked to Prostate Cancer ADT
- Second-Line Antidiabetic Meds May Impact Cardiovascular Risk
- Hemodialysis Patients May Benefit by Staying on Loop Diuretics
- High Uric Acid Predicts AKI, Mortality in Hospitalized Patients
- PCa Phenotype May Predict Response to Immune Checkpoint Blockade
- Roxadustat Effective in Chronic Kidney Disease Patients With Anemia
- Coronary Artery Calcium May Help Predict CVD in South Asians
- American College of Physicians Releases 7th Edition of Ethics Manual
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)